Compare Caesars Entertainment Inc (CZR) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Caesars Entertainment Inc vs GeneDx Holdings Corp — how do they compare? Caesars Entertainment Inc trades at $29.5 (market cap $6.02B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Caesars Entertainment Inc is far larger — about 3× GeneDx Holdings Corp's market cap, and Caesars Entertainment Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Caesars Entertainment Inc for 31 Days and GeneDx Holdings Corp for 19 Days on average.
| CZR | WGS | |
|---|---|---|
Market Cap | $6.02B | $2.02B |
Volume | 6,412,151 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $30.41 | $167.51 |
52-Week Low | $18.14 | $34.51 |
Typical Hold Time | 31 Days | 19 Days |
Enterprise Value | $29.91B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CZR trades at $29.52, up 0.1% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $502 million in 2025, with negative profit margins and consecutive earnings misses. A pending merger with Fertitta Entertainment at $31 per share is under regulatory review, while analyst consensus is mixed with a $30.75 price target.
The outlook is cautious due to persistent losses and high debt, though cash flow from operations remains positive. Risks include merger uncertainty and competitive pressures, but the stock trades below some valuation metrics, offering potential upside if profitability improves post-merger.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
